Jade Biosciences (JBIO)
NASDAQ:JBIO
Want to see JBIO full AI Analyst Report?
Top Page
Jade Biosciences
(NASDAQ:JBIO)
Select Model
Select Model
Rating:58Neutral
Price Target:
$23.00
▲(0.66% Upside)
Action:ReiteratedDate:04/30/26
The score is held back mainly by weak financial performance (no revenue, widening losses, and sizable cash burn) despite a strong low-debt balance sheet. Technicals are a near-term positive with the stock trading above key moving averages and positive MACD. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data, while the recent inducement equity plan is a modest positive but introduces dilution considerations.
Positive Factors
Low leverage / strong balance sheet
A very low debt load versus a large equity base gives the company durable financial flexibility: lower interest burden, capacity to absorb R&D spending, and the ability to pursue partnerships or staged financing without immediate solvency pressure, supporting program continuity over months.
Negative Factors
No revenue; widening losses
Absence of commercial revenue makes the business outcome highly binary and dependent on clinical success. Rapidly widening losses increase reliance on external capital, raising the risk that clinical setbacks or funding disruptions could materially impair the company’s ability to sustain development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A very low debt load versus a large equity base gives the company durable financial flexibility: lower interest burden, capacity to absorb R&D spending, and the ability to pursue partnerships or staged financing without immediate solvency pressure, supporting program continuity over months.
Read all positive factors
Jade Biosciences (JBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21B
Dividend Yield14.68%
Average Volume (3M)127.19K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue GrowthN/A
EPS Growth93.63%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.22
Shares Outstanding49,316,288
10 Day Avg. Volume252,880
30 Day Avg. Volume127,195
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.47K
Enterprise Value/Ebitda-7.99
Forecast
1Y Price Target
$32.50Price Target Upside42.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.08
Revenue Forecast (FY)N/A
Jade Biosciences Business Overview & Revenue Model
Company Description
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway fo...
How the Company Makes Money
null...
Jade Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -26.00K | -282.00K | -96.00K | -68.00K | -15.00K |
| EBITDA | -113.54M | -69.29M | -75.37M | -51.42M | -22.95M |
| Net Income | -127.41M | -69.63M | -75.52M | -51.51M | -22.96M |
Balance Sheet | |||||
| Total Assets | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M |
| Cash, Cash Equivalents and Short-Term Investments | 336.16M | 78.62M | 122.44M | 129.22M | 167.38M |
| Total Debt | 724.00K | 417.00K | 675.00K | 1.09M | 574.00K |
| Total Liabilities | 17.26M | 3.90M | 17.96M | 8.56M | 2.94M |
| Stockholders Equity | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M |
Cash Flow | |||||
| Free Cash Flow | -94.89M | -71.20M | -56.92M | -39.32M | -27.58M |
| Operating Cash Flow | -94.69M | -71.20M | -56.78M | -39.12M | -27.40M |
| Investing Cash Flow | -247.01M | 56.03M | 11.88M | 6.93M | -113.43M |
| Financing Cash Flow | 360.77M | 25.43M | 46.00M | 396.00K | 190.46M |
Jade Biosciences Technical Analysis
Positive
22.85
Price Trends
15.16
Positive
14.90
Positive
11.82
Positive
Market Momentum
1.79
Negative
83.14
Negative
91.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBIO, the sentiment is Positive. The current price of 22.85 is above the 20-day moving average (MA) of 16.43, above the 50-day MA of 15.16, and above the 200-day MA of 11.82, indicating a bullish trend. The MACD of 1.79 indicates Negative momentum. The RSI at 83.14 is Negative, neither overbought nor oversold. The STOCH value of 91.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JBIO.
Jade Biosciences Risk Analysis
Jade Biosciences disclosed 59 risk factors in its most recent earnings report. Jade Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jade Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.21B | -4.04 | -64.64% | 14.68% | ― | 93.63% | |
52 Neutral | $556.73M | -4.97 | -26.87% | ― | ― | 50.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $267.09M | -4.62 | -69.63% | ― | 76.18% | -109.46% | |
44 Neutral | $205.32M | -1.53 | -424.76% | ― | ― | 83.69% | |
43 Neutral | $150.74M | -12.08 | 25.65% | ― | ― | 35.99% | |
40 Underperform | $67.53M | -3.51 | -69.20% | ― | ― | -69.60% |
* Healthcare Sector Average
JBIO
Jade Biosciences
24.52
14.43
143.01%
GALT
Galectin Therapeutics
2.29
0.93
68.38%
IMMP
Immutep
0.46
-1.57
-77.29%
CLLS
Cellectis SA
3.70
2.12
134.18%
TECX
Tectonic Therapeutic
29.65
10.73
56.71%
HUMA
Humacyte
0.92
-0.31
-24.88%
Jade Biosciences Corporate Events
Executive/Board Changes
Jade Biosciences Elevates Andrew King to R&D President
Neutral
Apr 22, 2026
On April 18, 2026, Jade Biosciences, Inc. appointed Andrew King, BVMS, Ph.D. as President, Research Development, formalizing his leadership over the company’s scientific programs. Dr. King, who previously served as Chief Scientific Officer ...
Business Operations and Strategy
Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
Positive
Apr 2, 2026
On March 31, 2026, Jade Biosciences, Inc.’s board approved the 2026 Employment Inducement Stock Incentive Plan, modeled largely on its 2025 Stock Incentive Plan but excluding incentive stock options and limiting eligibility to employees qual...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.